Jakafi Xr Tablet, Extended Release
NDC Package 50881-044-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Jakafi Xr (ruxolitinib) tablets is none. This formulation utilizes a tablet, extended release delivery system. Marketed by Incyte Corporation, this product is identified by NDC 50881-044 and is authorized under FDA application NDA217180.

Identification & Billing

NDC Package Code
50881-044-08
Package Description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
Product Code
50881-044
11-Digit Billing Format
50881004408
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Jakafi Xr
Non-Proprietary Name
Ruxolitinib
Substance Name
Ruxolitinib
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
RUXOLITINIB 44 mg/1
Pharmacologic Class
Usage Information
None.

Regulatory & Marketing

Labeler Name
Incyte Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA217180
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50881-044-08 identifies a specific commercial package of 30 tablet, extended release in 1 bottle, plastic of Jakafi Xr, a human prescription drug labeled by Incyte Corporation. This tablet, extended release is formulated for oral use and contains ruxolitinib as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Incyte Corporation on May 01, 2026. The current certification is valid through December 31, 2027.

How is this Incyte Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50881004408. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
50881-044-08
11-Digit CMS (5-4-2)
50881-0044-08

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.